Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00292084
Status:
COMPLETED
Last Update Posted:
2008-01-21
First Post:
2006-02-13
Brief Title:
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b With or Without Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
Sponsor:
BioWest Therapeutics Inc
Organization:
BioWest Therapeutics Inc
Study Overview
Official Title:
A Phase II Multi-Center Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b With or Without Ribavirin for an Additional 36 Weeks
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an extension study of HCV-05-002 The objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b with or without ribavirin for an additional 36 weeks in patients with chronic hepatitis C genotype 1 infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None